Your selection

Innovation / 08.11.2022
Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in the same period of the previous year, in which the sale and associated deconsolidation of the tumor irradiation device division generated one-off income of approximately EUR 9.4 million. Adjusted for this one-time effect, consolidated net income attributable to EZAG shareholders increased by around 18% year-on-year from EUR 19.7 million to EUR 23.3 million. This increase in earnings was due to favorable exchange rates as well as higher sales of industrial products and radiopharmaceuticals.

The Isotope Products segment generated sales of EUR 102.7 million, up EUR 29.6 million (+40%) compared to the first nine months of 2021. All main product groups contributed to this good performance. The development of oil and gas prices is boosting the exploration activities of energy companies and, consequently, the demand for measurement components. Around EUR 7.9 million of the increase was attributable to the acquisition of the Argentine company Tecnonuclear SA; a further EUR 7.0 million was due to a favorable US dollar exchange rate (+12% on average between the first three quarters of 2021 and 2022)

Sales of EUR 65.5 million in the Medical segment during the first nine months of the year were around 6% higher than last year (EUR 61.6 million). The main growth driver continues to be the pharmaceutical radioisotopes business. Sales of laboratory equipment and plant engineering also increased significantly.

Despite the positive nine-month figures, the Executive Board continues to adhere to its previous sales and earnings forecast for the fiscal year 2022 of around EUR 200 million and around EUR 27 million, respectively. This position is based on the currently tense and risky global economic situation.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz322e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives

Overview News

News Buch Berlin

FyoniBio, Alder Therapeutics, and BioLamina enter Consortium Grant Agreement to Propel Recombinant Human Laminin Development for Clinical Applications

FyoniBio, a contract development organization (CDO) specializing in customized cell line and process development has partnered with BioLamina, a biotech company renowned for its expertise in extracell...

more ...

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreeme...

more ...

Third ERC Grant for Gaetano Gargiulo

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max D...

more ...

Events Buch Berlin

30.03.2024, 15:00
Osterfeuer auf dem historischen Stadtgut Berlin-Buch

19.04.2024, 08:30
Lehrkräftekongress: Gemeinsam Schüler:innen für Naturwissenschaften begeistern - gemeinsam Zukunft gestalten

Der Verband der Chemischen Industrie e.V., Landesverband Nordost, das Max Delbrück Center, das Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V., das Gläserne La...

more ...

06.05.2024, 09:00
Realtime PCR und digital PCR Kurs

Der RealTime PCR und Digital PCR Kurs richtet sich an erfahrene PCR Anwender*innen und an Einsteiger*innen. Wichtige PCR Grundlagen werden erörtert, bevor die RealTime PCR besprochen und Genexpression...

more ...

This website is supported by: